The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Precigen, Inc. is $12.50, about 89.1% above its August 3 closing price of $6.61
The stock recently traded at 67 times the next 12-month earnings vs. a P/E of 230 three months ago
PGEN•
